| Release date: November 2007 Expiration date: November 30, 2008 Estimated time to complete activity: 1.5 hours |
Read through all material and click "Begin Activity" at the bottom of the page. |
Sponsored by
Support for this activity has been provided through an educational grant from
Activity Overview
The heterogeneity of gliomas and the molecular pathophysiology that influences disease progression and tumor aggressiveness contribute to the challenge physicians face in making treatment decisions. The role of current and new molecular targets in glioma with respect to diagnosis, prognosis, and therapeutic intervention will be addressed. Additionally, this activity will provide key clinical considerations about molecular targets to assist radiation oncologists in their daily practice.
Target Audience
This activity has been designed to meet the educational needs of radiation oncologists and other health care professionals involved in the care and treatment of patients with brain cancer.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the diagnostic and prognostic significance of molecular markers expressed in patients with glioma
- Discuss clinical advances in the treatment of patients with newly diagnosed or relapsed/refractory high-grade and low-grade glioma
- Evaluate clinical data on the appropriate use of chemotherapy and/or radiation therapy for patients with glioma
Jay S. Loeffler, MD, FACR View biography
Herman & Joan Suit Professor of Radiation Oncology
Harvard Medical School
Chief, Department of Radiation Oncology
Massachusetts General Hospital
Boston, Massachusetts
FACULTY
Lawrence R. Kleinberg, MD View biography
Co-Director Stereotactic Radiosurgery
Associate Professor of Radiation Oncology and Neurosurgery
Department of Radiation Oncology and Molecular Radiation Sciences
Johns Hopkins University
Baltimore, Maryland
Dennis C. Shrieve, MD, PhD View biography
Professor and Chair, Department of Radiation Oncology
Huntsman Cancer Institute
University of Utah School of Medicine
Salt Lake City, Utah
Accreditation Statement
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Curatio CME Institute designates this educational activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians should not claim credit for this activity if credit was previously claimed for the symposium on which this Web activity is based.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period November 2007 to November 30, 2008, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest, and (4) complete the activity evaluation form, including the certificate information section.
You will then be able to print or store your AMA PRA Category 1 Credit certificate for this activity. Please e-mail any questions to cmeinfo@curatiocme.com
Medium
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the target audience.
Disclosure
In accordance with the ACCME’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Jay S. Loeffler, MD, FACR has disclosed no relevant financial relationships.
Lawrence R. Kleinberg, MD has disclosed the following relevant financial relationships:
| Research Support: | Abbott Labs, Astra-Zeneca |
Dr. Kleinberg will discuss the unlabeled or investigational use of a commercial product.
Dennis C. Shrieve, MD, PhD has disclosed no relevant financial relationships.
Curatio CME Institute Staff
Thomas Finnegan, PhD, Medical Writer, has disclosed no relevant financial relationships.
Danielle Hesser, Program Manager, has disclosed no relevant financial relationships.
Barbara Landers, Vice President, Medical Education Programs, has disclosed no relevant financial relationships.
Denise C. LaTemple, PhD, Vice President, Scientific Services, has disclosed no relevant financial relationships.
Brett Mutschler, CME Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Disclaimer
The information presented at this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute and Schering-Plough Corporation do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute and Schering-Plough Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Generic Name |
Trade Name |
Approved Use (if any) |
Unapproved/ |
AG014699 |
NA |
NA |
In combination with |
Cediranib (AZD2171) |
RecentinTM |
NA |
Patients with recurrent glioblastoma |
Carmustine, |
BiCNU® |
As palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: brain tumors (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors); multiple myeloma, in combination with prednisone; Hodgkin’s disease, as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who do not respond to primary therapy; non-Hodgkin’s lymphomas, as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy, or who do not respond to primary therapy. |
In combination with |
Cetuximab
|
Erbitux® |
In combination with radiation therapy for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck. As monotherapy, for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck for whom prior platinum-based therapy has failed. In combination with irinotecan, for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. As monotherapy, for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy. |
In patients with recurrent glioblastoma multiforme |
Erlotinib
|
Tarceva® |
As monotherapy, for the treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least 1 prior chemotherapy regimen. In combination with gemcitabine, for the first-line treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer. |
In patients with recurrent glioblastoma multiforme |
Gefitinib |
Iressa® |
As monotherapy, for the continued treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from Iressa. |
In combination with |
Temozolomide
|
Temodar® |
For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment. For the treatment of adult patients with refractory anaplastic astrocytoma. |
In combination with AG014699 in patients with malignant melanoma |
Hardware/Software Requirements
- Javascript-enabled browser
- Active Internet connection
- Adobe Acrobat Reader
- Adobe Flash Player plugin v.8.0+
Privacy Policy
Curatio CME Institute collects the information provided by the user. The information is used to provide notification about upcoming programs and educational information that may be of interest to our users. The information is not shared with others for commercial purposes, unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as the time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation and issuance of certification of CME/CE tests submitted. By participating in the Web-based activity, you agree that Curatio CME Institute has full permission to provide this minimum subset of information to third parties as required by law.
For CME questions, please contact cmeinfo@curatiocme.com or call (610) 363-1619 ext. 113. If you experience technical difficulties, please contact helpdesk@axis-healthcare.com.